NASDAQ:ARGS - Argos Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2701 +0.12 (+79.95 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$0.1451
Today's RangeN/A
52-Week Range$0.1375 - $9.40
VolumeN/A
Average Volume565,535 shs
Market Capitalization$2.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Argos Therapeutics logoArgos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina.

Receive ARGS News and Ratings via Email

Sign-up to receive the latest news and ratings for ARGS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARGS
CUSIPN/A
Phone919-287-6300

Debt

Debt-to-Equity Ratio-1.31
Current Ratio1.80
Quick Ratio1.80

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.90 million
Price / Sales1.12
Cash FlowN/A
Price / CashN/A
Book Value($1.63) per share
Price / Book-0.17

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-40,570,000.00
Net Margins-2,135.68%
Return on EquityN/A
Return on Assets-171.85%

Miscellaneous

Employees39
Outstanding Shares7,910,000
Market Cap$2.29

Argos Therapeutics (NASDAQ:ARGS) Frequently Asked Questions

What is Argos Therapeutics' stock symbol?

Argos Therapeutics trades on the NASDAQ under the ticker symbol "ARGS."

When did Argos Therapeutics' stock split? How did Argos Therapeutics' stock split work?

Argos Therapeutics shares reverse split on the morning of Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of Argos Therapeutics stock prior to the reverse split would have 5 shares after the split.

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics Inc. (NASDAQ:ARGS) posted its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) earnings per share for the quarter, topping the Zacks' consensus estimate of ($4.50) by $0.30. The biopharmaceutical company earned $0.07 million during the quarter, compared to the consensus estimate of $0.10 million. View Argos Therapeutics' Earnings History.

What is the consensus analysts' recommendation for Argos Therapeutics?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Argos Therapeutics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Argos Therapeutics' key competitors?

Who are Argos Therapeutics' key executives?

Argos Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey D. Abbey, Pres, CEO & Director (Age 56)
  • Dr. Charles A. Nicolette Ph.D., Chief Scientific Officer and VP of R&D (Age 56)
  • Dr. Richard D. Katz, VP & CFO (Age 54)
  • Ms. Lori R. Harrelson CPA, VP of Fin. & Principal Accounting Officer (Age 49)
  • Mr. John D. Menditto, VP of Corp. Communications and Investor Relations

Has Argos Therapeutics been receiving favorable news coverage?

News headlines about ARGS stock have trended somewhat positive recently, Accern reports. Accern identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Argos Therapeutics earned a news impact score of 0.11 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 45.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Argos Therapeutics?

Shares of ARGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Argos Therapeutics' stock price today?

One share of ARGS stock can currently be purchased for approximately $0.2701.

How big of a company is Argos Therapeutics?

Argos Therapeutics has a market capitalization of $2.29 million and generates $1.90 million in revenue each year. Argos Therapeutics employs 39 workers across the globe.

How can I contact Argos Therapeutics?

Argos Therapeutics' mailing address is 4233 TECHNOLOGY DR, DURHAM NC, 27704. The biopharmaceutical company can be reached via phone at 919-287-6300.


MarketBeat Community Rating for Argos Therapeutics (NASDAQ ARGS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  243 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  393
MarketBeat's community ratings are surveys of what our community members think about Argos Therapeutics and other stocks. Vote "Outperform" if you believe ARGS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Featured Article: Short Selling

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.